
Opinion|Videos|March 6, 2025
Comparing Approved ADC Options in HER2-Negative and HER2-Low Breast Cancer
Panelists discuss how antibody-drug conjugates (ADCs) for breast cancer (BC) differ in their safety profiles, with trastuzumab deruxtecan (T-DXd) having notable interstitial lung disease risk, sacituzumab govitecan (SG) associated with neutropenia/diarrhea, and datopotamab deruxtecan (Dato-DXd) showing a relatively favorable safety profile but still requiring monitoring.
Advertisement
Episodes in this series

Video content above has been prompted by the following:
- Could you walk through the ADC therapies that are approved for HR+ HER2-negative/low and triple-negative BC?
- What key differences in the safety of T-DXd, SG, and Dato-DXd are important for pharmacists to understand?
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Yes, COVID-19 Is Still a Big Deal. Pharmacy Is the Tip of the Spear (and Needle)
2
Beat the Heat: 10 Common Medication Culprits Causing Heat Intolerance
3
FDA Fast Tracks First-in-Class TNFR2 Antibody as Chemotherapy-Free Strategy for Platinum-Resistant Ovarian Cancer
4
The Inflation Reduction Act and Oncology Drug Pricing: What Pharmacists Need to Know
5



































































































